María Pilar
Garrido López
Profesor/a Asociado/a en CC. de la Salud
Hospital Universitario Marqués de Valdecilla
Santander, EspañaPublications en collaboration avec des chercheurs de Hospital Universitario Marqués de Valdecilla (18)
2024
-
Concordance in the estimation of tumor percentage in non-small cell lung cancer using digital pathology
Scientific Reports, Vol. 14, Núm. 1
-
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1779-1789
2022
-
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program
Oncotarget, Vol. 13, Núm. 1, pp. 812-827
2021
-
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888
2020
-
Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 167-181
-
Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 22, Núm. 7, pp. 989-1003
2019
-
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study
Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132
2017
-
Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions
Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 341-356
-
Erratum to: Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions (Clin Transl Oncol, 10.1007/s12094-016-1535-8)
Clinical and Translational Oncology
-
Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists
Clinical and Translational Oncology, Vol. 19, Núm. 4, pp. 508-518
2015
2014
-
Accurate identification of ALK positive lung carcinoma patients: Novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry
PLoS ONE, Vol. 9, Núm. 9
-
Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 17, Núm. 2, pp. 103-112
2012
-
Guidelines for biomarker testing in advanced non-small-cell lung cancer. A National Consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP)
Clinical and Translational Oncology, Vol. 14, Núm. 5, pp. 338-349
-
Recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón no microcítico avanzado. Consenso nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica
Revista Espanola de Patologia
2011
-
Consenso de la Sociedad Española de Anatomía Patológica (SEAP) y de la Sociedad Española de Oncología Médica (SEOM) sobre la determinación de HER2 en el carcinoma gástrico
Revista Espanola de Patologia, Vol. 44, Núm. 1, pp. 32-48
-
Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma
Clinical and Translational Oncology, Vol. 13, Núm. 9, pp. 636-651
2009
-
SEOM guidelines for the management of non-small-cell lung cancer (NSCLC)
Clinical and Translational Oncology